You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 20, 2024

Zydus Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Zydus
International Patents:4
US Patents:1
Tradenames:298
Ingredients:289
NDAs:368
Patent Litigation for Zydus: See patent lawsuits for Zydus

Drugs and US Patents for Zydus

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE empagliflozin; metformin hydrochloride TABLET;ORAL 212198-004 Jul 7, 2022 DISCN No No ⤷  Sign Up ⤷  Sign Up
Zydus Pharms BREXPIPRAZOLE brexpiprazole TABLET;ORAL 213660-001 Jan 10, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up
Zydus Pharms OLANZAPINE olanzapine TABLET;ORAL 090459-004 Jul 16, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up
Zydus Lifesciences DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 212299-001 Sep 10, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up
Zydus Pharms BUSPIRONE HYDROCHLORIDE buspirone hydrochloride TABLET;ORAL 078888-005 Mar 21, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up
Zydus TOPIRAMATE topiramate CAPSULE, EXTENDED RELEASE;ORAL 208949-003 Nov 29, 2022 AB2 RX No No ⤷  Sign Up ⤷  Sign Up
Zydus Pharms LENALIDOMIDE lenalidomide CAPSULE;ORAL 210154-003 Sep 12, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for ZYDUS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03

Supplementary Protection Certificates for Zydus Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2187879 CA 2017 00019 Denmark ⤷  Sign Up PRODUCT NAME: KOMBINATION AF EMPAGLIFLOZIN OG LINAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/16/1146/001-018 20161115
1452524 300815 Netherlands ⤷  Sign Up PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
1452524 CR 2016 00013 Denmark ⤷  Sign Up PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073/001-022 20160118
1020454 10C0022 France ⤷  Sign Up PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
2487162 300861 Netherlands ⤷  Sign Up PRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN EN DARUNAVIR, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN. IN HET BIJZONDER DARUNAVIRETHANOLAAT; REGISTRATION NO/DATE: EU/1/14/967 20141121
0136011 2000C/027 Belgium ⤷  Sign Up PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1084705 C01084705/04 Switzerland ⤷  Sign Up PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.